Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542200 · ClinicalTrials.gov registry record
Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 40,132
- Enrollment target
NCT04542200 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 40,132 participants.
The verdict
NCT04542200 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 40,132 participants
- Enrollment target
Study Summary
The goal, with this study, is to leverage Northwell Health System's diverse workforce and robust testing structures, to contribute data-driven, evidence-based strategies to better understand the sustained prevalence of antibodies and how conferred immunity may be modified by environmental factors. The objective is to investigate the COVID-19/SARS-CoV-2 disease prevalence and trajectory over time, by conducting follow-up antibody testing on employees who consented to participate in research during the initial workforce offering. From 70,812 employees contacted, 46,117 were tested and received initial results. Of those participants, approximately, 32,000 agreed to be re-contacted, and 34,000 consented to research. The investigators plan to conduct an additional five rounds of testing that would sample individuals over a two-year period. This study is significant because it leverages Northwell Health's advanced laboratory systems to conduct serosurveillance of antibodies to COVID-19/SARS-CoV-2 across a large and diverse workforce, while taking into account the contextual environmental and occupational exposures that may modify continued immunity to the virus. Northwell Health's employee health services (EHS) is poised to act quickly to adapt policies and practices, where needed, to protect the workforce. The study is also innovative because it will be linking work environment and community measures with COVID-19 seropositive prevalence patterns over time, to build a better understanding of the disease and its controls at the population level. The expected outcomes include serial serology results as a measure of full or partial short-term (6 months) and long-term (2 year) immunity to re-infection and recognition of local environmental factors (e.g., building ventilation rates, zip code, air quality indicators) that could modify this immunity and assist with protecting the workforce and surrounding community. These results could inform national and global policies.
Interventions
- BIOLOGICAL Antibody testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40,132 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2022-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04542200
The ClinicalTrials.gov registry entry for NCT04542200 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40,132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antibody testing is the first listed.
NCT04542200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04542200 about?
NCT04542200 is a clinical study titled "Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment". The goal, with this study, is to leverage Northwell Health System's diverse workforce and robust testing structures, to contribute data-driven, evidence-based strategies to better understand the sustained prevalence of antibodies and how conferred immunity may be modified by environmental factors. T...
What is the current status of trial NCT04542200?
This trial is currently completed. The enrollment target is 40,132 participants. The study started on 2021-01-01. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04542200?
The interventions under investigation include: Antibody testing (BIOLOGICAL).
Who is sponsoring clinical trial NCT04542200?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.